Close

Personalized Nutrition Market Growth: An Overview

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...
- Advertisement -

Personalized nutrition refers to the practice of tailoring dietary plans to an individual’s needs rather than the general population’s. Customized nutrition plans consider an individual’s age, sex, genetics, and health objectives. More people are becoming aware that a one-fit-all nutrition plan is not feasible as everyone has different requirements and goals.

In recent times, this industry has undergone rapid growth. People’s interest in maximizing their health and well-being through personalized nutrition plans has led to more people turning to it. In 2021, the global market value of the personalized growth market was 10.39 billion dollars. This has increased to 13.86 billion dollars in 2023 and is estimated to reach 38 billion dollars by 2030.

Why Personalized Nutrition?

The principal reason for the growth of the personalized nutrition market is the benefits it provides to the individual. Here are some reasons why people prefer customized nutrition plants and supplements over traditional options:

  1. Health Concerns: Some clients have a specific health condition that will benefit from a personalized nutrition plan. For instance, individuals with diabetes will be looking for a low-sugar diet plan to manage their condition better. Similarly, someone with high blood pressure will be looking for a low-sodium diet to keep it under control.
  2. Weight Management: Personalized nutrition plans can aid individuals in managing their weight by controlling their calorie intake and diet. Personalized plans take into account age, activity level, medical conditions, and other factors. These plans also advise portion size and meal times to help clients stick to a schedule.
  3. Convenience: There has been an increasing trend in online education, especially in the post-covid era. More students are taking advantage of online programs such as the Lamar masters program in nutrition science. As a result, more nutritionists are available to cater to the increased demand.
  4. Athlete Performance: Athletes have different requirements than ordinary people. Their high physical activity means they need a balanced, high-calorie, healthy diet. Nutrition experts can develop personalized nutrition plans to help them perform optimally and avoid injuries. A customized diet plan can help athletes optimize their performance by providing the right mix of nutrients to support their training.

A personalized diet plan can help athletes enhance recovery after strenuous workouts or injuries.

  1. Personal Preference: Some people like the idea of personalized nutrition plans as they feel they have been explicitly customized to their needs. This can motivate them to in pursuing a healthy lifestyle and work out.

Factors Driving the Market Growth

The critical factor driving growth in the personalized nutrition market is increased patient awareness. People have started understanding the link between diet and overall personal health. As the access to the internet is expanding, people are becoming more educated about the advantages of individualized diet plans. Personalized nutrition plans can help people better manage chronic illnesses such as diabetes, obesity, and cardiac issues. As a result, demand has increased, leading to the industry’s growth.

Another factor leading to growth in the personalized nutrition sector is the development of new technologies. Advancements such as gene-based nutrition and the use of AI to create diet plans specific to an individual have yielded positive results. Research into more such technologies is ongoing. Companies are working hard to come up with technologies to help make more accurate recommendations.

The demand for healthier food also leads to this field’s growth. People are turning toward more natural and organic options. Nutrition companies are providing these alternatives, leading to an increase in their popularity.

Increased availability of personalized nutrition products and services has resulted in more people opting for them. This has been a critical factor in driving the growth of this sector.

Some Key Players in the Market

Several companies are providing personalized nutrition plans to their clients. Here are some companies that offer unique services:

  1. Nutrigenomix: This company offers DNA-based nutritional testing and personalized nutrition plans based on those results.
  2. DNAFit: This company offers DNA-based fitness and nutrition plans, including personalized meal plans and workout recommendations.
  3. Platejoy: This company offers personalized meal planning and delivery services based on individual dietary preferences and goals.
  4. One Drop: This company offers a mobile app and coaching services for managing diabetes through personalized nutrition and lifestyle recommendations. Age is one of the factors considered when creating these plans.
  5. WellnessFX: This company offers various health and wellness services, including personalized nutrition plans based on DNA testing and other data points.
  6. MyFitnessPal: This popular app and website offer personalized nutrition tracking and goal-setting tools, as well as an extensive database of food and exercise information.

Market Segmentation

The term “market segmentation” describes breaking a market into subsets of consumers with common traits or demands. In the case of the personalized nutritional market, segmentation can be done based on the following;

  • Product Type: Offered products provide a valuable criterion for dividing the personalized nutrition market. Dietary supplements, functional foods, meal replacement shakes, and nutritional bars are some of the products that can be categorized as a separate segment.
  • Application: The personalized nutrition market can also be segmented based on the application or use of the products. For instance, sports, weight management, clinical, children, and elderly nutrition can be considered separate segments.
  • End user: Another factor in classifying the personalized nutrition industry is the type of end user who will be investing in these goods. This can either be consumers or health care professionals.

The consumer segment includes individuals who purchase nutrition products and services for their health. Healthcare professional segment includes professionals who work in the healthcare industry and prescribe personalized nutrition products and services to their patients.

Conclusion

In conclusion, the market for customized nutrition has experienced rapid expansion in recent years and is predicted to do so going forward. As more people look for custom-fit solutions to their health and diet, the market for personalized nutrition will only grow.

The market is still nascent and faces several obstacles and unknowns that could impede its development. There may still be mistrust or uncertainty on the part of consumers, as well as barriers posed by regulations. However, despite these barriers, the industry is still expected to grow as more people seek a profession. Industry leaders must recognize the limitations and work to overcome them to expand their services to a broader population.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »